Velan Capital Investment Management LP Makes New Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Velan Capital Investment Management LP bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 35,000 shares of the company’s stock, valued at approximately $77,000. Ventyx Biosciences comprises approximately 0.1% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 29th biggest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Catalina Capital Group LLC acquired a new position in shares of Ventyx Biosciences during the 4th quarter valued at about $25,000. AXQ Capital LP acquired a new position in shares of Ventyx Biosciences during the 4th quarter valued at about $29,000. Palumbo Wealth Management LLC raised its holdings in Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock valued at $52,000 after buying an additional 11,792 shares during the period. MetLife Investment Management LLC raised its holdings in Ventyx Biosciences by 76.0% in the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company’s stock valued at $59,000 after buying an additional 11,543 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in Ventyx Biosciences by 23.3% in the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock valued at $90,000 after buying an additional 7,768 shares during the period. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Trading Up 3.6%

Shares of VTYX opened at $1.45 on Tuesday. The firm has a market cap of $103.18 million, a P/E ratio of -0.61 and a beta of 0.73. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $5.66. The company’s 50-day moving average price is $1.19 and its 200 day moving average price is $1.75.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09. Equities research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.